Treatment of Depression in Patients with Coronary Heart Disease

American Journal of Medicine

Volumn 119, Issue 7, 2006, Pages 567-573

  Vieweg, W Victor R ^a,b   Julius, Demetrios A ^a,b   Fernandez, Antony ^a,b   Wulsin, Lawson R ^c   Mohanty, Pramod K ^a,b   Beatty Brooks, Mary ^a   Hasnain, Mehrul ^d   Pandurangi, Anand K ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d Western Regional Integrated Health Authority   (Canada)

Author keywords

Antidepressants; Coronary heart disease; Depression; Treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; CATECHOLAMINE; DOPAMINE UPTAKE INHIBITOR; DULOXETINE; HYDROCORTISONE; MIRTAZAPINE; MOOD STABILIZER; NEFAZODONE; NICOTINE; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WARFARIN;

ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BEHAVIOR THERAPY; BIPOLAR DEPRESSION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATECHOLAMINE BLOOD LEVEL; CLINICAL FEATURE; COGNITIVE THERAPY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG INDICATION; EJACULATION DISORDER; ELECTROCONVULSIVE THERAPY; GASTROINTESTINAL SYMPTOM; HEART RATE VARIABILITY; HEART REHABILITATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; HYPONATREMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MAJOR DEPRESSION; MANIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PATIENT REFERRAL; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOTHERAPY; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SINUS BRADYCARDIA; SOCIAL SUPPORT; SYNCOPE; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT GAIN; AUTONOMIC NERVOUS SYSTEM; BLOOD; CORONARY ARTERY DISEASE; DECISION MAKING; DEPRESSION; PHYSIOLOGY; PROGNOSIS; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR;

ANTIDEPRESSIVE AGENTS; AUTONOMIC NERVOUS SYSTEM; CATECHOLAMINES; CORONARY DISEASE; DECISION MAKING; DEPRESSIVE DISORDER; HUMANS; HYDROCORTISONE; PATIENT COMPLIANCE; PLATELET ACTIVATION; PROGNOSIS; RISK FACTORS;

EID: 33745927711     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.02.037     Document Type: Note

References (49)

1. Murray C.J.L., and Lopez A.D. Global mortality, disability, and the contribution of risk factors. global burden of disease study. Lancet 349 (1997) 1436-1442
2. Carney R.M., Freedland K.E., Miller G.E., and Jaffe A.S. Depression as a risk factor for cardiac mortality and morbidity. A review of potential mechanisms. J Psychosom Res 53 (2000) 897-902
3. Carney R.M., Freedland K.E., Rich M.W., and Jaffe A.S. Depression as a risk factor for cardiac events in established coronary heart disease. a review of possible mechanisms. Ann Behav Med 17 (1995) 142-149
4. Glassman A.H., and Shapiro P.A. Depression and the course of coronary artery disease. Am J Psychiatry 155 (1998) 4-11
5. Schleifer S.J., Macari-Hinson M.M., Coyle D.A., et al. The nature and course of depression following myocardial infarction. Arch Intern Med 149 (1989) 1785-1789
6. Wulsin L.R. Is depression a major risk factor for coronary disease? A systematic review of the epidemiologic evidence. Harv Rev Psychiatry 12 (2004) 79-93
7. Wulsin L.R., Vieweg W.V.R., and Fernandez A. Brain/body connection. Treating depression in patients with cardiovascular disease. Curr Psychiatry 3 (2004) 20-34
8. Musselman D.L., Evans D.L., and Nemeroff C.B. The relationship of depression to cardiovascular disease. epidemiology, biology and treatment. Arch Gen Psychiatry 55 (1998) 580-592
9. Empana J.P., Sykes D.H., Luc G., et al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men. The prospective epidemiological study of myocardial infarction (PRIME). Circulation 111 (2005) 2299-2305
10. Shimbo D., Child J., Davidson K., et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 89 (2002) 331-333
11. Cerrito F., Lazzaro M.P., Guadio E., Arminio P., and Aloisi G. 5HT2-receptors and serotonin release. their role in human platelet aggregation. Life Sci 53 (1993) 209-215
12. Nemeroff C.B., Knight D.L., Franks J., Craighead W.E., and Krishman K.R.R. Further studies on platelet serotonin transporter binding in depression. Am J Psychiatry 151 (1994) 1623-1625
13. Nemeroff C.B. The corticotropin-releasing factor (CRF) hypothesis of depression. new findings and new directions. Mol Psychiatry 1 (1996) 336-342
14. Roy A., Pickar D., Linnoila M., and Potter W.Z. Plasma norepinephrine level in affective disorders. relationship to melancholia. Arch Gen Psychiatry 42 (1985) 1181-1185
15. Roy A., Guthrie S., Pickar D., and Linnoila M. Plasma norepinephrine responses to cold challenge in depressed patients and normal controls. Psychiatry Res 21 (1987) 161-168
16. Gorman J.M., and Sloan R.P. Heart rate variability in depressive and anxiety disorders. Am Heart J 140 Suppl 4 (2000) 77-83
17. Carney R.M., Blumenthal J.A., Stein P.K., et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 104 (2001) 2024-2028
18. Carney R.M., Blumenthal J.A., Freedland K.E., et al. Low heart rate variability and the effect of depression on post-myocardial infarction mortality. Arch Intern Med 165 (2005) 1486-1491
19. Klein E., Cnaani E., Harel T., Braun S., and Ben-Haim S.A. Altered heart rate variability in panic disorder patients. Biol Psychiatry 37 (1995) 18-24
20. Cripps T.R., Malik M., Farrell T.G., and Camm A.J. Prognostic value of reduced heart rate variability after myocardial infarction. clinical evaluation of a new analysis method. Br Heart J 65 (1991) 14-19
21. George M.S., Rush A.J., Marangell L.B., et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treat-resistant depression. Biol Psychiatry 58 (2005) 364-373
22. Van Ravenswaaij-Arts C.M., Kollee L.A., Hopman J.C., Stoelinga G.B., and van Geijn H.P. Heart rate variability. Ann Intern Med 118 (1993) 436-447
23. Dalack G.W., and Roose S.P. Perspectives on the relationship between cardiovascular disease and affective disorder. J Clin Psychiatry 51 Suppl (1990) 4-9
24. Viskin S., and Belhassen B. Noninvasive and invasive strategies for the prevention of sudden death after myocardial infarction. value, limitations and implications for therapy. Drugs 44 (1992) 336-355
25. Sloan R.P., Shapiro P.A., Bagiella E., Myers M.M., and Gorman J.M. Cardiac autonomic control buffers blood pressure variability responses to challenge. a psychophysiologic model of coronary artery disease. Psychosom Med 61 (1999) 58-68
26. Frasure-Smith N., Lesperance F., and Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 91 (1995) 999-1005
27. Cuellar A.K., Johnson S.L., and Winters R. Distinctions between bipolar and unipolar depression. Clin Psychology Rev 25 (2005) 307-339
28. Taylor C.B., Youngblood M.E., Catellier D., et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62 (2005) 792-798
29. Glassman A.H. Does treating post-myocardial infarction depression reduce medical mortality?. Arch Gen Psychiatry 62 (2005) 711-712
30. Serebruany V.L., Glassman A.H., Malinin A.I., et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 5 (2003) 517-521
31. Glassman A.H. Cardiovascular effects of antidepressant drugs. updated. Int Clin Psychopharmacol 13 Suppl 5 (1998) S25-S30
32. Fricchione G.L., Woznicki R.M., Klesmer J., and Vlay S.C. Vasoconstrictive effects and SSRIs. J Clin Psychiatry 54 (1993) 71-72
33. Harvey A.T., Rudolph R.L., and Preskorn S.H. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57 (2000) 503-509
34. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E., Nielsen S.T., and Sigg E.B. Antidepressant biochemical profile of the novel bicyclic compound Wy-45 030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35 (1986) 4493-4497
35. Thase M.E. Effects of venlafaxine on blood pressure. a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 59 (1998) 502-508
36. Nemeroff C.B., Schatzberg A.F., Goldstein D.J., et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36 (2002) 106-132
37. Martyn R., Somberg J.C., and Kerin A.Z. Proarrhythmia of nonantiarrhythmic drugs. Am Heart J 126 (1993) 201-205
38. Andrews J.M., and Nemeroff C.B. Contemporary management of depression. Am J Med 97 (1994) 24S-32S
39. Blier P. Pharmacology of rapid onset antidepressant treatment strategies. J Clin Psychiatry 63 Suppl 15 (2001) 12-17
40. Roose S.P., Dalack G.W., Glassman A.H., Woodring S., Walsh B.T., and Giardina E.G. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 148 (1991) 512-516
41. Arroll B., Khin N., and Kerse N. Screening for depression in primary care with two verbally asked questions. cross sectional study. BMJ 327 (2003) 1144-1146
42. Lesperance F., and Frasure-Smith N. Depression in patients with cardiac disease. a practical review. J Psychosom Res 48 (2000) 379-391
43. Gehi A., Haas D., Pipkin S., and Whooley M.A. Depression and medication adherence in outpatients with coronary heart disease. Arch Intern Med 165 (2005) 2508-2513
44. Schulberg H.C., Katon W., Simon G.E., and Rush A.J. Treating major depression in primary care practice. an update of the agency for health care policy and research practice guidelines. Arch Gen Psychiatry 55 (1998) 1121-1127
45. Henderson M., Glozier N., and Elliott K.H. Long term sickness absence is caused by common conditions and needs managing. BMJ 330 (2005) 802-803
46. Kemp D.E., Malhotra S., Franco K.N., Tesar G., and Bronson D.L. Heart disease and depression. don't ignore the relationship. Cleve Clin J Med 70 (2003) 745-761
47. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition (2000), American Psychiatric Association, Washington, DC text revision
48. Endicott J. Measurement of depression in patients with cancer. Cancer 53 Suppl 10 (1984) 2243-2249
49. Cavanaugh S. Depression in the medically ill. critical issues in diagnostic assessment. Psychosomatics 36 (1995) 48-59